Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

Detalles Bibliográficos
Autores principales: Wallace, Katrine, Goble, Sandra, Isaacson, Jeff, Maloney, Lara, Cameron, Terri, Bedel, Josh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830408/
https://www.ncbi.nlm.nih.gov/pubmed/31172449
http://dx.doi.org/10.1007/s40273-019-00815-3
_version_ 1783465776228859904
author Wallace, Katrine
Goble, Sandra
Isaacson, Jeff
Maloney, Lara
Cameron, Terri
Bedel, Josh
author_facet Wallace, Katrine
Goble, Sandra
Isaacson, Jeff
Maloney, Lara
Cameron, Terri
Bedel, Josh
author_sort Wallace, Katrine
collection PubMed
description
format Online
Article
Text
id pubmed-6830408
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-68304082019-11-20 Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” Wallace, Katrine Goble, Sandra Isaacson, Jeff Maloney, Lara Cameron, Terri Bedel, Josh Pharmacoeconomics Letter to the Editor Springer International Publishing 2019-06-07 2019 /pmc/articles/PMC6830408/ /pubmed/31172449 http://dx.doi.org/10.1007/s40273-019-00815-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Wallace, Katrine
Goble, Sandra
Isaacson, Jeff
Maloney, Lara
Cameron, Terri
Bedel, Josh
Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
title Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
title_full Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
title_fullStr Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
title_full_unstemmed Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
title_short Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
title_sort comment on: “cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the united states”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830408/
https://www.ncbi.nlm.nih.gov/pubmed/31172449
http://dx.doi.org/10.1007/s40273-019-00815-3
work_keys_str_mv AT wallacekatrine commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates
AT goblesandra commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates
AT isaacsonjeff commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates
AT maloneylara commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates
AT cameronterri commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates
AT bedeljosh commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates

Ejemplares similares